Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
3
38%
Ph early_phase_1
1
13%
Ph phase_2
4
50%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(2)
Other(1)

Detailed Status

Recruiting3
Completed2
Active, not recruiting1
Not yet recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 13 (37.5%)
Phase 24 (50.0%)

Trials by Status

active_not_recruiting113%
recruiting338%
not_yet_recruiting113%
suspended113%
completed225%

Recent Activity

4 active trials
Showing 5 of 8
recruitingphase_2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465
recruitingphase_2

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

NCT04082520
suspendedphase_1

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

NCT07150806
active_not_recruitingearly_phase_1

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

NCT04040088
recruitingphase_1

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

NCT07150546
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05691465Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Recruiting
NCT04082520Phase 2

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Recruiting
NCT07150806Phase 1

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Suspended
NCT04040088Early Phase 1

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

Active Not Recruiting
NCT07150546Phase 1

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Recruiting
NCT04529044Phase 2

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Not Yet Recruiting
NCT03448458Phase 2

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Completed
NCT03953131Phase 1

Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas

Completed

All 8 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
8